| Detailed information |
|---|
| CancerLivER ID | 2208 |
| Biomarker | SULT1A3/4 |
| Biomarker Name/Symbol (given in Publication) | SULT1A3/4 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | potential biomarker of early diagnosis and progression of HCC; but not validated on independent daatset |
| Experimental Condition | HCC v/s Normal; associated with metastatsis of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 29025375 |
| Type of Biomarker | Prognostic |
| Pathway | enzymes that conjugate sulfonic xenobiotics and facilitate their elimination |
| Cohort | 9 pairs of HCC tumors and the adjacent tissues; Human liver cancer cell lines (MHCC97-L and MHCC97-H, HepG2) |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human liver cancer |
| Year of Publication | 2017 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |